ADMA Biologics (ADMA) Stock

Adma Biologics (ADMA) closed the most recent trading day at $16.17, moving -0.12% from the previous trading session.

Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.

The major tech stocks known as the Magnificent Seven, along with leading AI companies, contributed to significant growth in many large-cap mutual funds. One of the top funds achieved a return of 51.8%.

ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.

Adma Biologics (ADMA) closed at $18.56 in the latest trading session, marking a +1.48% move from the prior day.

We have just put together a list of the 12 Best Multibagger Stocks to Invest in at the moment. In this article, we will examine how ADMA Biologics, Inc. (NASDAQ:ADMA) compares to the other multibagger stocks. The US stock market has been rising in 2024, helping the S&P 500 reach new record levels.

ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc., and ChromaDex are featured in the Zacks top Analyst Blog.

Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.

Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA's Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla.